Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
.jpg?sfvrsn=205a5de0_2 "Castration resistant prostate cancer cells stained for a number of key driver molecules. (Mateus Crespo, Gerhardt Attard and Johann de Bono / the ICR, 2012)")
First men invited to take part in the most ambitious prostate cancer trial in decades
Today, the first men have been invited to join the ambitious £42 million TRANSFORM screening trial, kicking off the biggest prostate cancer screening study in a generation.
New computational breakthrough helps uncover how water molecules influence cancer drug potency
In a major step forward for cancer drug discovery, researchers have demonstrated how computational simulations can unravel the complex role of water molecules in drug binding, potentially saving years of trial and error in the lab.
.jpg?sfvrsn=83f9c0d2_1 "human-cells-with-acute-myelocytic-leukemia-(aml)")
Why men fare worse in acute myeloid leukaemia: new study rules out hormone signalling
New research has ruled out hormone signalling as the reason why men with acute myeloid leukaemia (AML) tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy – a finding that helps refine future research and could influence clinical trial design.
Embracing mathematics is key to illuminating cancer cell evolution
A new review explains how turning to mathematics is helping researchers decode one of cancer’s most elusive traits: its ability to evolve and adapt.